Abstract: Disclosed is a non-natural amatoxin-type antibody conjugate, said conjugate similar to the natural amatoxin is linked to a biopharmaceutically acceptable salt with a target biomolecule so as to obtain stability in blood plasma, and efficiently kill tumor cells in cells.

Abstract: The present application provides a novel thyroid hormone ß receptor agonist having better activity, selectivity or safety and represented by formula (I), and use thereof in preventing or treating a disease related to the ß receptor agonist. The disease comprises, for example, obesity, hyperlipidemia, hypercholesterolemia, diabetes, the liver disease (fatty liver, NASH, NAFLD, etc.), the cardiovascular disease (atherosclerosis, etc.), the thyroid disease (hypothyroidism, thyroid cancer, etc.), etc.

Abstract: By inserting cysteine (C) into a heavy chain and/or a light chain of a target antibody at specific insertion site, and performing a site-specific conjugation through a free thiol group (—SH) from the site-specific inserted cysteine and a linker conjugated with a highly potent small molecule cytotoxin, a cysteine modified antibody-drug conjugate with good homogeneity is provided. The specific insertion sites of cysteine are position 205 and/or position 206 (Kabat numbering scheme) of the light chain of the antibody, and/or position 439 (Kabat numbering scheme) of the heavy chain.

Abstract: Disclosed in the present invention is a cysteine-modified antibody-toxin conjugate. The cysteine-modified antibody-toxin conjugate is characterized in that: the antibody is an antibody in which cysteine is inserted on a fixed point, and insertion sites of the cysteine comprising one or more of the following sites: a 110th site, a IIIth site and a 142th site of a light chain in a Kappa/?L light chain constant region, and a 254th site, a 255th site, a 258th, a 259th site, a 354th site, a 355th site, a 357th site, a 378th site, a 379th site, a 386th site, a 387th site or a 410th site of a heavy chain of a heavy chain constant region of an IgG antibody.

Abstract: A bicyclic octapeptide derivative is conjugated to a corresponding target-binding group by a special chemical structure. The structure of the derivative is stable in blood plasma and decomposes into a drug as an active ingredient in a specific biological environment, thereby maximizing killing effect on target cells and minimizing toxic side effects on non-target cells. The derivative can be used in the treatment of various malignant tumors.

Abstract: Disclosed is a non-natural amatoxin-type antibody conjugate, said conjugate similar to the natural amatoxin is linked to a biopharmaceutically acceptable salt with a target biomolecule so as to obtain stability in blood plasma, and efficiently kill tumor cells in cells.

Abstract: By inserting cysteine (C) into a heavy chain and/or a light chain of a target antibody at specific insertion site, and performing a site-specific conjugation through a free thiol group (—SH) from the site-specific inserted cysteine and a linker conjugated with a highly potent small molecule cytotoxin, a cysteine modified antibody-drug conjugate with good homogeneity is provided.